Table 1.
Variable | No. of patients (%) | 5-year OS (%) | P | 5-year EFS (%) | P |
---|---|---|---|---|---|
Sex | |||||
Male | 69 (68) | 58 | 0.30 | 47 | 0.12 |
Female | 33 (32) | 67 | 65 | ||
Age, years | |||||
Median | 27.56 | ||||
Range | 18–60 | ||||
18–25 | 46 (45) | 57 | 0.68 | 50 | 0.87 |
26–35 | 32 (31) | 63 | 53 | ||
36+ | 24 (24) | 64 | 56 | ||
Primary tumor site | |||||
Extremities | 51 (50) | 60 | 0.90 | 52 | 0.95 |
Pelvis | 17 (17) | 58 | 53 | ||
Axial | 34 (33) | 63 | 53 | ||
Primary tumor site | |||||
Nonosseous | 32 (31) | 60 | 0.65 | 52 | 0.72 |
Osseous | 70 (69) | 60 | 52 | ||
Tumor size | |||||
<8 cm | 38 (58) | 60 | 0.96 | 50 | 0.77 |
≥8 cm | 27 (42) | 60 | 57 | ||
Treatment era | |||||
1977–1992 | 50 (49) | 49 | 0.01* | 45 | 0.08 |
1993–2007 | 52 (51) | 73 | 60 | ||
LC modality | |||||
Surgery | 43 (42) | 71 | 0.27 | 66 | 0.15 |
RT | 25 (25) | 49 | 37 | ||
S + RT | 34 (33) | 57 | 48 | ||
IE chemotherapy | |||||
No | 37 (42) | 51 | 0.11 | 45 | 0.30 |
Yes | 52 (58) | 66 | 56 | ||
Histopathologic response to chemotherapy | |||||
<95% necrosis | 24 (56) | 49 | 0.04* | 46 | 0.04* |
≥95% necrosis | 19 (44) | 83 | 77 | ||
Surgical margins | |||||
Clear | 58 (85) | 69 | 0.008* | 60 | 0.009* |
Involved | 10 (15) | 25 | 30 | ||
RT dose (cGy) (definitive RT only) | |||||
<5600 | 19 (83) | 50 | 0.85 | 38 | 0.81 |
≥5600 | 4 (17) | 50 | 25 |
*Statistically significant.